Technology stocks were advancing pre-bell Tuesday, with the State Street Technology Select Sector SPDR Fund (XLK) up 0.3% and the State Street SPDR S&P Semiconductor ETF (XSD) 2% higher.
CrowdStrike (CRWD) shares were up more than 1% after the company said it has expanded its go-to-market strategy across Japan and Asia Pacific, aiming to boost cybersecurity adoption among small and medium-sized businesses, or SMBs.
Energy stocks were mixed late Monday afternoon with the NYSE Energy Sector Index rising 0.2% and the State Street Energy Select Sector SPDR ETF (XLE) shedding 0.1%.The Philadelphia Oil Service Sector Index fell 0.8%, and the Dow Jones US Utilities Index fell 0.6%.West Texas Intermediate crude oil jumped 5.9% to $88.79 a barrel, and global benchmark Brent rose 5.3% to $95.19 a barrel. Henry Hub natural gas futures increased 0.3% to $2.68 per 1 million BTU.In corporate news, Devon Energy (DVN) shares rose 1.3% after Tudor Pickering Holt upgraded the stock to buy from hold with a $63 price target.USA Rare Earth (USAR) agreed to acquire Brazilian rare earths miner Serra Verde in a cash-and-stock deal with an equity value of about $2.8 billion. USA Rare Earth shares jumped 13%.Eni (E) and Repsol reached a deal with the Venezuelan government to begin exporting natural gas from the country's Perla field in the Gulf of Venezuela, shipping the fuel in the form of liquefied natural gas from a floating terminal, Bloomberg reported. Separately, Eni made a gas discovery in the Kutei Basin off the coast of Indonesia. Eni shares rose 0.4%.Sable Offshore (SOC) shares climbed 3.4% after it said capital expenditures across its assets are expected to be around $180 million from April through December.
Financial stocks were mixed in late Monday afternoon trading, with the NYSE Financial Index decreasing 0.1% and the State Street Financial Select Sector SPDR ETF (XLF) adding 0.3%.The Philadelphia Housing Index was rising 0.7%, and the State Street Real Estate Select Sector SPDR ETF (XLRE) was up 0.2%.Bitcoin (BTC-USD) was climbing 3.3% to $76,265, and the yield for 10-year US Treasuries was slightly higher at 4.25%.In corporate news, Intercontinental Exchange-backed (ICE) predictions site Polymarket is in talks to raise about $400 million at a valuation of roughly $15 billion, including the new proceeds, The Information reported. Intercontinental Exchange shares were down 0.5%.Sila Realty Trust (SILA) agreed to be acquired and taken private by affiliates of Blue Owl Capital's (OWL) real estate unit in an all-cash deal worth roughly $2.4 billion. Sila shares jumped 19%, and Blue Owl was up 0.5%.Apollo Global Management (APO) has agreed to invest $1.25 billion in convertible preferred equity in McKesson's (MCK) Medical-Surgical Solutions business, acquiring about a 13% minority stake as part of the unit's planned separation, McKesson said Monday. Apollo shares rose nearly 2%.Blackstone-backed (BX) Jersey Mike's Subs said Monday that it has confidentially filed a draft registration statement with the US Securities and Exchange Commission for a proposed initial public offering. Blackstone shares were decreasing 0.2%.
Health care stocks declined late Monday afternoon, with the NYSE Health Care Index down 1.1% and the State Street Health Care Select Sector SPDR ETF (XLV) shedding 1%.The iShares Biotechnology ETF (IBB) decreased 0.4%.In corporate news, Tvardi Therapeutics (TVRD) shares fell 4.1% after Barclays downgraded the company's stock to underweight from equalweight and adjusted the price target to $3 from $4.Eli Lilly (LLY) has agreed to buy clinical-stage biotechnology firm Kelonia Therapeutics for up to $7 billion, as the drugmaker looks to bolster its cancer treatment portfolio. Lilly shares were easing 0.6%.Compass Pathways (CMPS), GH Research (GHRS), and other psychedelic companies' shares were up on Monday, after US President Donald Trump signed an executive order Saturday to expedite access to treatments for patients with serious mental illness. Compass shares surged 42%, and GH Research jumped 17%.Nektar Therapeutics (NKTR) shares climbed 18% after it said Monday that data from a 16-week extension period of its phase 2b study of rezpegaldesleukin showed a "deepening of response" in people with severe-to-very-severe alopecia areata.